sj-pdf-1-tam-10.1177_17588359211012361 – Supplemental material for Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice

Brückl, Wolfgang M.; Reck, Martin; Griesinger, Frank; Schäfer, Harald; Kortsik, Cornelius; Gaska, Tobias; Rawluk, Justyna; Krüger, Stefan; Kokowski, Konrad; Budweiser, Stephan; Ficker, Joachim H.; Hoffmann, Christopher; Schüler, Andrea; Laack, Eckart

doi:10.25384/SAGE.14565286.v1

sj-pdf-1-tam-10.1177_17588359211012361.pdf (475.72 kB)

sj-pdf-1-tam-10.1177_17588359211012361 – Supplemental material for Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice

journal contribution

posted on 2021-05-10, 12:16 authored by Wolfgang M. Brückl, Martin Reck, Frank Griesinger, Harald Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Joachim H. Ficker, Christopher Hoffmann, Andrea Schüler, Eckart Laack

Supplemental material, sj-pdf-1-tam-10.1177_17588359211012361 for Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice by Wolfgang M. Brückl, Martin Reck, Frank Griesinger, Harald Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Joachim H. Ficker, Christopher Hoffmann, Andrea Schüler and Eckart Laack in Therapeutic Advances in Medical Oncology